Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16

INTRODUCTION: Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by heterogeneous clinical phenotypes and high symptom burden, especially through itch. Baricitinib (BARI), an oral Janus Kinase 1/2 inhibitor, is approved in Europe, Japan, and other countries, for treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Thyssen, Jacob P., de Bruin-Weller, Marjolein, Costanzo, Antonio, Grond, Susanne, Schuster, Christopher, Liu, Chunyuan, Rueda, Maria Jose, Chen, Yun-Fei, Pinter, Andreas, Bieber, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329959/
https://www.ncbi.nlm.nih.gov/pubmed/37332021
http://dx.doi.org/10.1007/s12325-023-02528-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329959/
https://www.ncbi.nlm.nih.gov/pubmed/37332021
http://dx.doi.org/10.1007/s12325-023-02528-8

Ejemplares similares